Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: LGND stock price vs GS: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at GS's multiple
Needs GS P/E.
Implied fair value · at LGND's multiple
Needs LGND P/E.
Live quote
Price unavailable
Metric by metric
Filter, sort, and scan the equity metrics that matter most for banks: book value, tangible book, returns, and operating efficiency.
Lower is better
Lower is better
Profitability lag
Asset efficiency edge
Lower is better
Statements
Bank-focused income statement and equity metrics aligned to the reporting windows.
SEC periods: LGND FY 2025 (ended Dec 31, 2025) · GS FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Tangible book and profitability anchor a bank, not enterprise value.
Deposits and cash-like balances distort enterprise value for banks, so this section reads equity value, tangible book and profitability instead.
Price / book
Market cap
—
Tangible equity
$690.23M
Price / tangible book
—
Price / book
—
Return on equity
12.2%
Return on assets
8.0%
Efficiency ratio
—
Price / book
Market cap
—
Tangible equity
$118.18B
Price / tangible book
—
Price / book
—
Return on equity
13.7%
Return on assets
0.9%
Efficiency ratio
64.4%
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
LIGAND PHARMACEUTICALS INCORPORATED · implied price per share
Bear
$101.45
Base
$119.35
Bull
$137.25
The Goldman Sachs Group, Inc. · implied price per share
Bank model off — standard DCF modelling is disabled for financial institutions.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.25x
2.45x
Net debt / EBITDA
Leverage against operating earnings
-2.31x
0.86x
Cash and equivalents
Liquid reserves on the balance sheet
$733.52M
$173.54B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider banking comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
$252.03M
$305.74B
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe LGND can sustain 60.4% revenue growth and preserve its 46.4% net margin, then hold or own it despite the premium; otherwise, reduce exposure because the current price of $319.59 is far above the P/E-implied value of $121.96 and above the DCF range.
LGND trades at a steep premium to GS on both earnings and sales multiples, which is hard to justify solely from the data provided. The current price of $319.59 sits above GS-implied range and near the top of its historical band, while the P/E-based implied price points to substantial downside.
Supporting Metrics
